Why did CMPS stock drop? Compass Pathways faced an abrupt decline after its latest financial and drug trial results. The company is developing psilocybin-based treatments for a variety of illnesses.
Who bought CMPs stock?
Nov 09, 2021 · Compass Pathways ( CMPS -0.80% ) saw its shares drop more than 22% on Tuesday. The biotech stock, which focuses on mental health treatment, closed at $43.06 on Monday, opened at $40.65 on Tuesday ...
What was the earnings per share for Compass pathways (CMPs)?
Oct 05, 2021 · The company is pursuing a psychoactive treatment for depression using psilocybin, the active ingredient in psychedelic (or "magic") mushrooms. Though there was no real negative news to explain the...
What is compass pathways'(Comp) stock price potential upside?
Apr 03, 2022 · Earnings for COMPASS Pathways are expected to decrease in the coming year, from ($2.85) to ($3.37) per share. Price to Earnings Ratio vs. the Market. The P/E ratio of COMPASS Pathways is -6.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Will compass pathways (CMPs) outperform or underperform the S&P 500?
AGF Investments Inc. boosted its stake in COMPASS Pathways by 937,652.9% during the third quarter. AGF Investments Inc. now owns 637,672 shares of the company's stock worth $19,047,000 after ...
Is CMPS stock a good buy?
Out of 6 analysts, 4 (66.67%) are recommending CMPS as a Strong Buy, 2 (33.33%) are recommending CMPS as a Buy, 0 (0%) are recommending CMPS as a Hold, 0 (0%) are recommending CMPS as a Sell, and 0 (0%) are recommending CMPS as a Strong Sell. What is CMPS's earnings growth forecast for 2022-2024?
Is Compass pathways a buy?
COMPASS Pathways has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Is Compass pathways publicly traded?
Psilocybin Magic Mushrooms are Now a Publicly Traded Investment Vehicle: COMPASS Pathways (NASDAQ:CMPS)Mar 28, 2022
How do I buy a compass pathways stock?
How to buy shares in COMPASS PathwaysCompare share trading platforms. Use our comparison table to help you find a platform that fits you.Open your brokerage account. Complete an application with your details.Confirm your payment details. ... Research the stock. ... Purchase now or later. ... Check in on your investment.
Who owns Compass pharmaceuticals?
Several years ago our co-founders, George Goldsmith and Ekaterina Malievskaia, experienced the painful effects of depression within their own family. They discovered first-hand how hard it can be to find adequate mental health care for a loved one, and met many other patients and families who felt similarly helpless.
Does Atai own compass pathways?
Atai bought another 619,095 Compass Pathways shares in recent days, taking its stake in the company from 19.4% to 20.8%. The new shares were bought at around $31 each and Atai paid around $12 million in total.Nov 29, 2021
Who is CMPS stock?
As of April 20 12:10PM EDT. Market open....Performance Outlook.Previous Close12.68Ask12.70 x 1200Day's Range12.29 - 12.7752 Week Range10.50 - 49.51Volume60,8163 more rows
When did compass pathways go public?
September 18th, 2020On September 18th, 2020 Compass Pathways was listed (NASDAQ:CMPS, ISIN:US20451W1018), making it the first psychedelic company to be listed on a U.S. exchange.Oct 1, 2020
Is Compass pathways a pharmaceutical company?
Compass Pathways Plc operates as a pharmaceutical company. The Company develops active substance psilocybin for the treatment of patients with treatment resistant depression.
How do I buy Compass pathways stock UK?
How to buy shares in COMPASS PathwaysChoose a platform. If you're a beginner, our share-dealing table below can help you choose.Open your account. ... Confirm your payment details. ... Search the platform for stock code: CMPS in this case.Research COMPASS Pathways shares. ... Buy your COMPASS Pathways shares.Nov 12, 2021
Is COMPASS Pathways a buy right now?
8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for COMPASS Pathways in the last year. There are currently 8 buy rati...
When is COMPASS Pathways' next earnings date?
COMPASS Pathways is scheduled to release its next quarterly earnings announcement on Thursday, May 12th 2022. View our earnings forecast for COMPA...
How were COMPASS Pathways' earnings last quarter?
COMPASS Pathways plc (NASDAQ:CMPS) announced its earnings results on Thursday, February, 24th. The company reported ($0.61) earnings per share for...
What price target have analysts set for CMPS?
8 Wall Street analysts have issued 12-month target prices for COMPASS Pathways' shares. Their forecasts range from $50.00 to $120.00. On average, t...
Who are COMPASS Pathways' key executives?
COMPASS Pathways' management team includes the following people: Mr. George Jay Goldsmith , Co-Founder, Chair of the Board & CEO (Age 67, Pay $7...
Who are some of COMPASS Pathways' key competitors?
Some companies that are related to COMPASS Pathways include Zentalis Pharmaceuticals (ZNTL) , Sage Therapeutics (SAGE) , Ironwood Pharmaceutical...
What other stocks do shareholders of COMPASS Pathways own?
Based on aggregate information from My MarketBeat watchlists, some companies that other COMPASS Pathways investors own include Nikola (NKLA) , Va...
When did COMPASS Pathways IPO?
(CMPS) raised $100 million in an IPO on Friday, September 18th 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Cow...
What is COMPASS Pathways' stock symbol?
COMPASS Pathways trades on the NASDAQ under the ticker symbol "CMPS."
Progress continues on the company's work to develop a mental health treatment using a psychoactive drug therapy
Howard grew up in Philadelphia watching the Philly sports teams struggle for championships. He has been investing since 1989 and been a Fool since 2001. Prior to joining The Fool as a contract writer in 2019, Howard worked in the steel business as an engineer for 28 years.
Key Points
The company is working to create a successful mental health therapy for 100 million patients in need.
What happened
Mental healthcare company Compass Pathways ( NASDAQ:CMPS) continues to work on developing a new model of psilocybin therapy. It's a gradual path, however, and the stock hasn't moved much overall since the company last provided a financial update on Aug. 11.
So what
The company is pursuing a psychoactive treatment for depression using psilocybin, the active ingredient in psychedelic (or "magic") mushrooms. Though there was no real negative news to explain the stock-price drop in the month, it effectively just gave back the gains seen since that second-quarter update.
Now what
The therapy is being developed for people who have not had success with other depression treatments. The Food and Drug Administration designated COMP360 with breakthrough therapy status in 2018, and the company has successfully completed its phase I trial.
About COMPASS Pathways
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression.
COMPASS Pathways (NASDAQ:CMPS) Frequently Asked Questions
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for COMPASS Pathways in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" COMPASS Pathways stock. View analyst ratings for COMPASS Pathways or view top-rated stocks.
What is the FDA designation for Comp360?
The United States Food and Drug Administration (FDA) has awarded CMPS’s COMP360 with the breakthrough therapy designation. This means COMP360 might not be mired in lengthy clinical development as sometimes occurs with other medicinal products.
How many people benefit from Comp360?
It is estimated that more than 100 million individuals across the globe can benefit from COMP360. There is also the potential for CMPS psychedelics to help individuals with maladies aside from depression. It is interesting to note CMPS will not strictly provide patients with only COMP360.
What is the lowest target price for CMPS?
The lowest target price for CMPS is $50. CMPS’s upside potential is 80% higher than the rest of the stocks traded in the United States. Furthermore, the average analyst price target for CMPS is greater than 93% of all small-cap stocks.
When did CMPS jump?
CMPS was trading in the mid-$30s in April, then jumped up to $39 on April 27. Profit-taking caused the stock to drop to $35 the next day. However, CMPS bounced right back to life, returning to $38.96 one day later. Unfortunately, CMPS has stagnated in the weeks since, trading between $36 and $32.
Where is compass pathways based?
COMPASS Pathways ( CMPS - Get Rating) is a mental healthcare business based in London, UK. However, CMPS principally operates in New York. CMPS is down nearly 30% year to date, presenting a potentially lucrative entry point for investors who have been waiting to establish a position in the stock.
Does CMPS provide Comp360?
It is interesting to note CMPS will not strictly provide patients with only COMP360. Rather, the drug will be provided in unison with the assistance of mental health professionals. The bottom line is no one knows for sure exactly how the general public will react to micro dosing psychedelics to overcome depression.
My theory on MindMed
If MindMed has all the legacy research. They must have some idea of the promise that LSD holds.
Why is this sub so dead?
I know we’re in a slow time and a downtrend but did everyone disappear? 21k+ members and I see the same 4 people in the chat every day…
